HEMATHEM
ActiveSummary
HEMATHEM has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €210,559 and a net result of €90,011. Equity is growing by about 77% per year across the filed financial years. Its solvency ranks better than 95% of 20,335 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
13-05
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
31-12
Financial
Liquidity doublescurrent ratio 38.29
Current ratio from 18.91 to 38.29; short-term debt falls from €6,743 to €5,589.
31-12
Financial
Equity above €200,000equity €210,559 ▲74.7%
A profit in every financial year since 2023 builds equity to €210,559.
16-05
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
31-12
Financial
Highest result from 2023 to 2025net €96,636 ▲440%
Operating result €124,417, net result €96,636, both a record.
31-12
Financial
Liquidity more than 5 timescurrent ratio 18.91
Current ratio from 3.29 to 18.91; short-term debt falls from €10,452 to €6,743.
31-12
Financial
Equity above €100,000equity €120,548 ▲404%
A profit in every financial year since 2023 builds equity to €120,548.
02-05
NBB filing
Annual accounts filed
financial year 2023 · micro format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.